Clinical Trial

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-02; most recent amendment 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-27
Trial Details
NCT Number NCT06398418
Lead Sponsor Rise Therapeutics LLC
Conditions Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer, Squamous Cell Cancer, Adenoma
Enrollment 33 participants
Start Date 2025-08-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04